Yamamoto M, Sudoh K, Sasamata M
Central Research Laboratories, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.
Eur J Pharmacol. 1991 Jan 3;192(1):165-7. doi: 10.1016/0014-2999(91)90084-4.
The effects of YM-14673, a new thyroid-releasing hormone (TRH) analogue (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), on neurological deficits were examined in stroke-prone spontaneously hypertensive rats (SHRSP). The neurological deficits were evaluated for more than 21 days after stroke. Administration of YM-14673 was started the day stroke was observed and repeated daily for 3 weeks. YM-14673 (0.1 and 0.3 mg/kg i.p.) improved the neurological deficits and reduced mortality. These results demonstrate that YM-14673 mitigates cerebral ischemic changes in SHRSP.
研究了新型促甲状腺激素释放激素（TRH）类似物YM-14673（Nα-[[(S)-4-氧代-2-氮杂环丁烷基]羰基]-L-组氨酰-L-脯氨酰胺二水合物）对易卒中型自发性高血压大鼠（SHRSP）神经功能缺损的影响。在卒中后对神经功能缺损进行了超过21天的评估。在观察到卒中的当天开始给予YM-14673，并每天重复给药，持续3周。YM-14673（0.1和0.3mg/kg，腹腔注射）改善了神经功能缺损并降低了死亡率。这些结果表明，YM-14673可减轻SHRSP的脑缺血变化。
